IN THE SPOTLIGHT

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

How Can Patients and Researchers Design Clinical Trials Together?

How Can Patients and Researchers Design Clinical Trials Together?

Read time: 2 minutes.  Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials.  In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist…

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

2024 ASCO: Highlights of Lung Cancer Research

2024 ASCO: Highlights of Lung Cancer Research

Read time: 8 minutesThousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 through June 4, 2024. The theme for this year’s conference, “The Art and Science of Cancer Care: From Comfort to Cure,” highlighted the importance of using both our creativity and our scientific…

Is Lung Cancer in Young Adults Hereditary?

Is Lung Cancer in Young Adults Hereditary?

Read time: 2 minutesThe question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer diagnosis is approximately 70 years old, we are now seeing young adults in their 20s and 30s getting lung cancer.We currently suspect lung cancer in young adults may be caused by environmental factors (such as air pollution or chemical exposure), their genetic make-up, or some combination of these factors.We cannot say for…

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Frank Sierawski: A New Meaning for Father’s Day

Frank Sierawski: A New Meaning for Father’s Day

Read time: 3 minutesIt’s been nearly a decade since Frank Sierawski was diagnosed with stage IV lung cancer in his 30s. The Sierawski family—including Frank, his wife Kathryn, and their three kids—all experienced his diagnosis, treatment, and remission in different ways.“My kids have the luxury of not really remembering much of my treatments, surgery, brain radiation, etc. But my wife does. She remembers it like it was yesterday, and that's really given her some PTSD. You can imagine working…

Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer

Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer

Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed with advanced-stage lung cancer. Research is ongoing to help us develop effective options to treat these patients medically, but little is known about the effects of the diagnosis on their mental, social, and financial health or their family planning. To help us better understand the needs of this growing…

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti

Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti

Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation. Her involvement with the medical system from these different perspectives inspired her to write her recent book, Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System. You can watch the full 40-minute conversation with Kathy or use the timestamps below to learn more about the topics and advice…

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey

Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey

Read time: 2 minutesIntegrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of…

Highlights of AACR 2024: Where the Laboratory Meets the Patient

Highlights of AACR 2024: Where the Laboratory Meets the Patient

Read time: 7 minutesIt’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of you who are new to this meeting, it is the largest gathering of laboratory scientists and clinicians in the world—coming together to discuss how to take science from the bench (laboratory) to patients and communities. This year’s meeting was held in sunny San Diego and brought together more than 23,000 attendees. Below…

New Treatment Approved for Early-Stage ALK+ Lung Cancer

New Treatment Approved for Early-Stage ALK+ Lung Cancer

On April 18, 2024, the US Food and Drug Administration (FDA) announced the approval of alectinib to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC).The approval is supported by data from the phase 3 ALINA trial, which showed that treating patients with alectinib reduced the risk of disease recurrence by 76% compared to treating them with chemotherapy.Alectinib is approved for use in patients with completely resected stage IB to IIIA ALK-positive NSCLC…

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’

Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her…

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Caregivers: Planning the Self-Care Journey

Caregivers: Planning the Self-Care Journey

This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase.  The discussion features Michelle Bolden, founder and chief education officer for Call For Caring Inc., a nonprofit organization educating and uplifting family caregivers in Atlanta. Michelle also hosts two podcasts -- "Call For Caring on Purpose" and "The Empowerment Hour."  The webinar was recorded on March 7, 2024, as a Facebook Live event. It is hosted…

Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer

Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer

Read time: 4 minutesI just returned from the Cancer Grand Challenges Summit, held March 5–8, 2024 in London, England. Cancer Grand Challenges was launched in 2020 as a collaboration between Cancer Research UK and the National Cancer Institute in the US, whereby they provide $25 million to international, multi-institutional teams working to address some of the most perplexing issues in the cancer field. I am LUNGevity’s representative on Team CANCAN, which is working to understand and treat…

General Virtual Meetup

General Virtual Meetup

For patients/survivors - Join us every Tuesday for this general meetup for those impacted by lung cancer.Register in advance for this meeting:After registering, you will receive a confirmation email containing information about joining the meeting.

Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer

Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer

Read Time: 5 minutesIt’s a mystery that has been baffling researchers: Why do some people develop lung cancer in their 20s or 30s? While we used to think lung cancer was only caused by exposure to tobacco and environmental factors like radon, researchers are starting to learn that the development of lung cancer, particularly in younger adults, could have a hereditary component.  LUNGevity partnered with the Lung Cancer Initiative, a leading nonprofit in North Carolina, to support…